23 September 2025
\n \n \n \n53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
\n \n\n \n \n23 September 2025
\n \n \n \nPepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
\n \n\n \n \n17 September 2025
\n \n \n \nFirst phase completed a year earlier than typical industry timelines
\n \n\n \n \n12 September 2025
\n \n \n \nIn the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
\n \n\n \n \n10 September 2025
\n \n \n \nStay informed with the latest BioEscalator updates, tenant and alumni news in the Autumn 2025 edition of the BioEscalator Bulletin.
\n \n\n \n \n9 September 2025
\n \n \n \nWe are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
\n \n\n \n \n8 September 2025
\n \n \n \nFollows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
\n \n\n \n \n1 September 2025
\n \n \n \nCollaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
\n \n\n \n \n25 August 2025
\n \n \n \nOXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
\n \n\n \n \n21 August 2025
\n \n \n \nInfinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
\n \n\n \n \n19 August 2025
\n \n \n \nWe\u2019re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
\n \n\n \n \n19 August 2025
\n \n \n \nIcosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.
\n \n\n \n \n6 August 2025
\n \n \n \nTheolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.
\n \n\n \n \n6 August 2025
\n \n \n \nInfinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
\n \n\n \n \n5 August 2025
\n \n \n \nOMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
\n \n\n \n \n30 July 2025
\n \n \n \nIt was an afternoon of high drama as BioEscalator tenants took to the floor in our recent annual Pitch Battle to compete for the Best Pitch prize, sponsored by Oxford North, and a range of other accolades.
\n \n\n \n \n27 July 2025
\n \n \n \nU-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
\n \n\n \n \n23 July 2025
\n \n \n \nWho knew? Young adults do listen to their parents, and the BioEscalator is very glad about that. Becson Ody, our first Business Administration & Reception apprentice, found out about apprenticeships through his father, who is a \u2018big advocate\u2019.
\n \n\n \n \n20 July 2025
\n \n \n \nJLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.
\n \n\n \n \n13 July 2025
\n \n \n \nOMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
\n \n\n \n \n